This case examines the difficulties associated with marketing vaccines in low-income settings. The focus is on the dengue vaccine introduced in late 2015, which was first marketed in emerging countries. It takes into account affordability and sales issues and underscores the need for business model innovations in all industries.
In 2009, Crucell was the largest biopharmaceutical company in the Netherlands and a symbol of national pride. The case traces the development of the company from a university spin-off company to a fully integrated company. Crucell’s success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While working …
The case illustrates the efforts of the International Federation of the Red Cross and Red Crescent (IFRC) in the field of emergency preparedness. Provides an anecdotal account of the International Federation’s inability to respond promptly to the 1998 Hurricane Mitch disaster that struck Central America. He then describes how the disaster sparked the pilot initiative …
Dengvaxia, the recently approved dengue vaccine by Sanofi Pasteur, was unusual in that it was released in the Philippines and other vulnerable countries. In making the decision to change the model, in an emerging market environment rather than developed markets, he had to overcome several barriers along the value chain, from registration to financing to …
The case describes the first weeks of the 2014 Ebola outbreak in West Africa and describes how two organizations, the World Health Organization and Doctors Without Borders, assess the severity of the outbreak. Both organizations have knowledge and experience in containing epidemics, especially in previous Ebola outbreaks. However, these organizations reached radically contradictory conclusions. The …
It covered the AIDS epidemic, including background, treatment, drug prices, and the economy.
This case examines the difficulties associated with marketing vaccines in low-income settings. The focus is on the dengue vaccine introduced in late 2015, which was first marketed in emerging countries. It takes into account affordability and sales issues and underscores the need for business model innovations in all industries.
In late 2020, ImmunVX, a fictitious multinational vaccine company, was a leader in the development of a vaccine against the COVID19 virus. He had accepted several government grants to help cover the cost of faster development of the vaccine. The company had limited in-house manufacturing capacity, but had accepted orders from various governments that far …
The Crucell (B) case updates Crucell’s events since 2009. In September 2009, Johnson & Johnson acquired 18% of Crucell for $ 400 million. This investment was part of a business development agreement. Later, in 2012, Johnson & Johnson acquired Crucell for $ 2.8 billion.
Ray White is an Australian real estate company that has been owned and operated by the White family for four generations. The business has grown and flourished. But how should the White family react when the industry faces new challenges and opportunities? This case also describes how the company coped with the COVID19 crisis.